{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:55:42Z","timestamp":1786136142837,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009347","name":"Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physiology & Behavior"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.physbeh.2026.115412","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:54:09Z","timestamp":1780530849000},"page":"115412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Vortioxetine transiently alters basal locomotor activity but does not produce sedation in rats"],"prefix":"10.1016","volume":"315","author":[{"given":"Susana","family":"Barbosa-M\u00e9ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1787-1657","authenticated-orcid":false,"given":"Alberto","family":"Salazar-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.physbeh.2026.115412_bib0001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-017-0612-7","article-title":"Vortioxetine: clinical pharmacokinetics and drug interactions","volume":"57","author":"Chen","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.physbeh.2026.115412_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.physbeh.2026.115412_bib0003","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/pcn.13709","article-title":"Vortioxetine for depression in adults: a systematic review and dose-response meta-analysis of randomized controlled trials","volume":"78","author":"Yang","year":"2024","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.physbeh.2026.115412_bib0004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14740338.2022.2019705","article-title":"Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review","volume":"21","author":"De Diego-Adeli\u00f1o","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"issue":"12","key":"10.1016\/j.physbeh.2026.115412_bib0005","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4088\/JCP.14027ah1","article-title":"An overview of vortioxetine","volume":"75","author":"Schatzberg","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.physbeh.2026.115412_bib0006","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2147\/DDDT.S62912","article-title":"Altered \u03b3-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants","volume":"9","author":"Pehrson","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.physbeh.2026.115412_bib0007","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1017\/S1092852915000486","article-title":"Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission","volume":"21","author":"Pehrson","year":"2016","journal-title":"CNS Spectr."},{"issue":"2","key":"10.1016\/j.physbeh.2026.115412_bib0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S1092852915000139","article-title":"Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors)","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr."},{"issue":"4","key":"10.1016\/j.physbeh.2026.115412_bib0009","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1092852915000334","article-title":"Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr."},{"issue":"6","key":"10.1016\/j.physbeh.2026.115412_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1017\/S1092852915000358","article-title":"Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.physbeh.2026.115412_bib0011","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1017\/S1092852915000346","article-title":"Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.physbeh.2026.115412_bib0012","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3892\/etm.2023.12214","article-title":"Efficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: a systematic review and a meta\u2011analysis of randomized controlled trials","volume":"26","author":"Gao","year":"2023","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.physbeh.2026.115412_bib0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ijnp\/pyad018","article-title":"Effectiveness and safety of Vortioxetine for the treatment of major depressive disorder in the real world: a systematic review and meta-analysis","volume":"26","author":"Li","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.physbeh.2026.115412_bib0014","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1517\/14740338.2015.1046836","article-title":"Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorders","volume":"14","author":"Al-Sukhni","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.physbeh.2026.115412_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2025.104409","article-title":"Safety and tolerability of vortioxetine versus serotonin reuptake inhibitors in late life depression: a systematic review and meta-analysis","volume":"106","author":"Rodrigues Alessi","year":"2025","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.physbeh.2026.115412_bib0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13643-015-0001-y","article-title":"The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis","volume":"4","author":"Meeker","year":"2015","journal-title":"Syst. Rev."},{"key":"10.1016\/j.physbeh.2026.115412_bib0017","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/NDT.S41387","article-title":"Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder","volume":"10","author":"Alvarez","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.physbeh.2026.115412_bib0018","first-page":"523","article-title":"The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials","volume":"12","author":"Li","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.physbeh.2026.115412_bib0019","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00213-014-3633-z","article-title":"the efficacy and safety of 5 mg\/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis","volume":"232","author":"Fu","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.physbeh.2026.115412_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/YIC.0000000000000010","article-title":"Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study","volume":"29","author":"Alam","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.physbeh.2026.115412_bib0021","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.physbeh.2026.115412_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1617345","article-title":"Efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD: a retrospective multicenter study","volume":"16","author":"Martiadis","year":"2025","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.physbeh.2026.115412_bib0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pnpbp.2016.03.001","article-title":"Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism","volume":"68","author":"Smagin","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.physbeh.2026.115412_bib0024","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1331\/JAPhA.2012.12051","article-title":"Histamine-1 receptor antagonism for treatment of insomnia","volume":"52","author":"Van de Griend","year":"2012","journal-title":"J. Am. Pharm. Assoc."},{"issue":"1","key":"10.1016\/j.physbeh.2026.115412_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1592\/phco.27.1.89","article-title":"Therapeutic options for sleep-maintenance and sleep-onset insomnia","volume":"27","author":"Morin","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.physbeh.2026.115412_bib0026","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1358\/dot.2009.45.4.1358835","article-title":"Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin","volume":"45","author":"Owen","year":"2009","journal-title":"Drugs Today (Barc.)"},{"key":"10.1016\/j.physbeh.2026.115412_bib0027","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1142\/S0192415X1550041X","article-title":"Artemisia capillaris Thunberg produces sedative-hypnotic effects in mice, which are probably mediated through potentiation of the GABA (A) receptor","volume":"43","author":"De la Pe\u00f1a","year":"2015","journal-title":"Am. J. Chin. Med."},{"issue":"1","key":"10.1016\/j.physbeh.2026.115412_bib0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pnpbp.2016.02.010","article-title":"Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats","volume":"68","author":"Salazar-Ju\u00e1rez","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.physbeh.2026.115412_bib0029","article-title":"Measuring motor coordination in mice","volume":"75","author":"Deacon","year":"2013","journal-title":"J. Vis. Exp."},{"issue":"2","key":"10.1016\/j.physbeh.2026.115412_bib0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lfs.2005.12.045","article-title":"Comparison between multiple behavioral effects of peripheral ethanol administration in rats: sedation, ataxia, and bradykinesia","volume":"79","author":"Chuck","year":"2006","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.physbeh.2026.115412_bib0031","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02249408","article-title":"Different behavioral effects of haloperidol, clozapine, and thioridazine in a concurrent lever pressing and feeding procedure","volume":"125","author":"Salamone","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1016\/j.physbeh.2026.115412_bib0032","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.3390\/molecules26113242","article-title":"5-HT1A Serotonergic, \u03b1-adrenergic and opioidergic receptors mediate the analgesic efficacy of vortioxetine in mice","volume":"26","author":"Y\u00fccel","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.physbeh.2026.115412_bib0033","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21307\/ane-2019-002","article-title":"Antidepressant and anxiolytic efficacy of single, chronic, and concomitant use of vortioxetine, dapoxetine, and fluoxetine in prenatally stressed rats","volume":"79","author":"Ratajczak","year":"2019","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"key":"10.1016\/j.physbeh.2026.115412_bib0034","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3389\/fphar.2018.01024","article-title":"Vortioxetine differentially modulates MK-801-induced changes in visual signal detection task performance and locomotor activity","volume":"9","author":"Hillhouse","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.physbeh.2026.115412_bib0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuropharm.2014.10.015","article-title":"Involvement of 5-HT\u2087 receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents","volume":"89","author":"Westrich","year":"2015","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.physbeh.2026.115412_bib0036","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"3\u20134","key":"10.1016\/j.physbeh.2026.115412_bib0037","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00001756-199011000-00025","article-title":"Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice","volume":"1","author":"Misslin","year":"1990","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.physbeh.2026.115412_bib0038","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pbb.2009.07.008","article-title":"Sedation and antinociception induced by a new pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivative (LASSBio-873) is modulated by activation of muscarinic receptors","volume":"94","author":"Mendes","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.physbeh.2026.115412_bib0039","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.physbeh.2026.115412_bib0040","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S1092852900024020","article-title":"Mechanism of action of trazodone: a multifunctional drug","volume":"14","author":"Stahl","year":"2009","journal-title":"CNS Spectr."},{"key":"10.1016\/j.physbeh.2026.115412_bib0041","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v66n0409","article-title":"A review of the evidence for the efficacy and safety of trazodone in insomnia","volume":"66","author":"Mendelson","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.physbeh.2026.115412_bib0042","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1098612X15587956","article-title":"Use of oral trazodone for sedation in cats: a pilot study","volume":"18","author":"Orlando","year":"2016","journal-title":"J. Feline Med. Surg."},{"key":"10.1016\/j.physbeh.2026.115412_bib0043","first-page":"23","article-title":"Trazodone dosing regimen: experience with single daily administration","volume":"51","author":"Fabre","year":"1990","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.physbeh.2026.115412_bib0044","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1871530315666150623092031","article-title":"Weight gain and metabolic changes during treatment with antipsychotics and antidepressants","volume":"15","author":"Himmerich","year":"2015","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"issue":"4","key":"10.1016\/j.physbeh.2026.115412_bib0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3810\/pgm.2012.07.2577","article-title":"Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians","volume":"124","author":"Hasnain","year":"2012","journal-title":"Postgrad. Med."},{"issue":"4","key":"10.1016\/j.physbeh.2026.115412_bib0046","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bcpt.14058","article-title":"The effect of vortioxetine on faecal microbiota in high-fat diet-exposed mice-A link to weight protection","volume":"135","author":"Corfitsen","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.physbeh.2026.115412_bib0047","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1017\/S1092852916000626","article-title":"Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older","volume":"22","author":"Nomikos","year":"2017","journal-title":"CNS Spectr."},{"issue":"10","key":"10.1016\/j.physbeh.2026.115412_bib0048","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: comprehensive review and meta-analysis","volume":"71","author":"Serretti","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.physbeh.2026.115412_bib0049","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/fcp.12737","article-title":"Vortioxetine as an analgesic in preclinical inflammatory pain models: mechanism of action","volume":"36","author":"Todorovi\u0107","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.physbeh.2026.115412_bib0050","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuropharm.2014.10.015","article-title":"Involvement of 5-HT\u2087 receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents","volume":"89","author":"Westrich","year":"2015","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.physbeh.2026.115412_bib0051","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1139\/jpn.0427","article-title":"The therapeutic role of 5-HT1A and 5-HT2A receptors in depression","volume":"29","author":"Celada","year":"2004","journal-title":"J. Psychiatry Neurosci."}],"container-title":["Physiology & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938426001964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938426001964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:22:29Z","timestamp":1786134149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031938426001964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"alternative-id":["S0031938426001964"],"URL":"https:\/\/doi.org\/10.1016\/j.physbeh.2026.115412","relation":{},"ISSN":["0031-9384"],"issn-type":[{"value":"0031-9384","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vortioxetine transiently alters basal locomotor activity but does not produce sedation in rats","name":"articletitle","label":"Article Title"},{"value":"Physiology & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.physbeh.2026.115412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115412"}}